Resveratrol can enhance the anticancer effect of paclitaxel on NSCLC cells in vitro by reducing COX‐2 expression at mRNA and protein levels, indicating that resveratrol has the potential to be used as a promising sensitizer for PA.260. Here, PTGS2 is linked to non-small cell lung carcinoma.